Showing 1 - 1 of 1 Brain Cancers
A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (NCT03149003)

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Julie Baskin

Phone: 713.441.3800

This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) follow ... Read more >